Mexico: COFEPRIS Recognizes 2025 Advances of the Permanent Commission of the Mexican Pharmacopoeia

COFEPRIS acknowledged the advances achieved in 2025 by the Permanent Commission of the Mexican Pharmacopoeia (FEUM), Mexico’s official pharmacopoeial body responsible for developing and updating quality standards applicable to medicinal products. The announcement highlights ongoing efforts to strengthen pharmacopoeial specifications, analytical methods, and technical references that underpin regulatory compliance and product quality in the country.

The FEUM serves as a core technical reference within the Mexican regulatory framework, defining official standards related to identity, purity, potency, and testing methodologies for medicinal products. Although this update does not introduce new regulatory mandates or compliance deadlines, it reflects continued progress in the development and consolidation of pharmacopoeial standards formally recognized by COFEPRIS.

COFEPRIS’s decision to share this update underscores the authority’s role in reinforcing the importance of robust technical and scientific foundations that support regulatory oversight. By highlighting advancements in the FEUM, COFEPRIS signals the relevance of pharmacopoeial standards as a key element for ensuring quality, consistency, and predictability across the medicinal product lifecycle.

Key Highlights

• Pharmacopoeial Standards Development
  Recognition of continued progress in the development and updating of official pharmacopoeial standards, reinforcing the FEUM as a foundational technical reference for medicinal product quality in Mexico.
• Regulatory Alignment
  Supports consistency between pharmacopoeial standards and the national regulatory framework, contributing to regulatory predictability for manufacturers and regulatory stakeholders.
• Medicinal Products Scope
  Applicable to medicinal products subject to quality, specification, and analytical requirements defined by the FEUM and relevant across the product lifecycle.
• Non-Mandate Nature
  This update does not establish new regulatory obligations or compliance deadlines and should be understood as an institutional and technical update with regulatory relevance.

This recognition reflects COFEPRIS’s continued commitment to strengthening the scientific and technical standards that support medicinal product quality and effective regulatory oversight in Mexico.